Literature DB >> 8623227

FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A.

T Kawaguchi1, Y Hoshino, F Rahman, Y Amano, H Higashi, H Kataoka, M Ohtsuki, K Teshima, K Chiba, T Kakefuda, S Suzuki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8623227

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  7 in total

Review 1.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

2.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

3.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing.

Authors:  Y Yanagawa; Y Masubuchi; K Chiba
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

Review 4.  Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii.

Authors:  Kenji Chiba
Journal:  J Antibiot (Tokyo)       Date:  2020-07-17       Impact factor: 2.649

5.  Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.

Authors:  Yong-Mi Kim; Teviah Sachs; Wannee Asavaroengchai; Roderick Bronson; Megan Sykes
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.

Authors:  Kunitomo Adachi; Kenji Chiba
Journal:  Perspect Medicin Chem       Date:  2007-09-06

7.  Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.

Authors:  Kenji Chiba; Kunitomo Adachi
Journal:  Pharmaceuticals (Basel)       Date:  2012-05-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.